<DOC>
	<DOCNO>NCT02250170</DOCNO>
	<brief_summary>This open-label , non-randomized trial comprise 2 part . A dose escalation part characterize safety , biomarker pharmacokinetics OPB-111077 advance solid tumor . Subsequently , expansion part evaluate biomarker , safety , pharmacokinetics antitumor activity OPB-111077 select tumor type .</brief_summary>
	<brief_title>Safety Biomarker OPB-111077 Subjects With Advanced Solid Tumor</brief_title>
	<detailed_description>This trial design determine safety , tolerability , maximum tolerate dose recommend dose OPB-111077 administer orally 4-days 3-days ( 3 weeks/cycle ) subject advanced solid tumor dose escalation part biomarkers , efficacy , others evaluate recommend dose expeditious manner expansion part . The dose escalation part employ 3+3 escalation design standard dose escalation design small sample size .</detailed_description>
	<criteria>1 . Pathologically and/or cytologically confirm advanced solid tumor 2 . Patients refractory standard therapy standard treatment option available 3 . Age 20 80 year time inform consent 4 . Patients , together partner , willing capable use appropriate method contraception throughout trial period least 12 week final IMP administration 5 . Patients informed diagnosis advance solid tumor fully inform content study investigator subinvestigator use specify write consent form write explanation , give write consent participate study free 6 . Patients able take oral medication 1 . Patients symptomatic brain metastasis 2 . Patients recover prior therapy relate toxicity deem clinically significant study entry , except test item define inclusion criterion . 3 . Patients active infection need whole body therapy 4 . Patients positive hepatitis B surface ( HBs ) antigen positive hepatitis C virus ( HCV ) antibody 5 . Patients positive human immunodeficiency virus ( HIV ) antibody 6 . Patients uncontrollable cardiac diseases 7 . Patients uncontrollable pain analgesic drug 8 . Patients history organ transplantation 9 . Patients receive another IMP 10 . Patients pregnant , possibly pregnant , lactate 11 . Patients otherwise judge investigator subinvestigator inappropriate inclusion trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>